Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Brad S Kahl, Mehdi Hamadani, Paolo Caimi, Carmelo Carlo-Stella, Erin Reid, Jay Feingold, Kirit M Ardeshna, John Radford, Melhem M Solh, Ki-Young Chung, Leonard Heffner, Shui He, Joseph Boni and Owen Anthony O'Connor | ||||||||||||
Title | Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma | ||||||||||||
|
|||||||||||||
URL | http://www.bloodjournal.org/content/130/Suppl_1/187 | ||||||||||||
Abstract Text | Blood 2017 130(Suppl 1):187 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Durvalumab + Loncastuximab tesirine-lpyl | Durvalumab Loncastuximab tesirine-lpyl | 0 | 1 |
Ibrutinib + Loncastuximab tesirine-lpyl | Ibrutinib Loncastuximab tesirine-lpyl | 0 | 1 |
Loncastuximab tesirine-lpyl | Loncastuximab tesirine-lpyl | 0 | 6 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Loncastuximab tesirine-lpyl | Zynlonta | ADCT-402 | CD19 Antibody 20 | Zynlonta (loncastuximab tesirine-lpyl) is a human anti-CD19 antibody in conjugation with a pyrrolobenzodiazepine (PBD) dimer toxin, which may specifically target CD19-positive tumor cells (Blood 2017 130(Suppl 1):187, PMID: 32012214). Zynlonta (loncastuximab tesirine-lpyl) is FDA approved for use in patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy (FDA.gov). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|